Proactive Investors - Run By Investors For Investors
Market: AIM
52-week High/Low: 44.50p / 25.00p
Sector: Pharma & Biotech
Market Cap: 7.20M
Genedrive PLC

Genedrive PLC

The Genedrive® molecular diagnostic system has been developed as an affordable next generation genotyping and sequence analysis device, providing rapid detection in approximately 45-75 minutes depending on the test.
The first test developed on the Genedrive® is MTB/RIF which allows small/medium laboratories to test for TB thus speeding up diagnosis and treatment and improving prognosis.

Genedrive PLC

Interactive graph

col 3
col 4
col 5
col 6

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use